Synopsis
With more than 25 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 8th SCI / RSC symposium on kinases will encompass case studies of ongoing programmes as well as successful past programmes. A range of topics including CNS kinase inhibitors, allosteric inhibitors and non-oral delivery methods will be covered, along with views and perspectives on the future of kinase inhibitor research.
Attendees
This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.
Programme
Day 2 - 15th May 2018
Event Schedule
- 09:00
- Strategy and tactics for the discovery of Kinase inhibitors for CNS targets. A Lundbeck perspective Klaus Bæk Simonsen, Lundbeck
- 09:40
- Building on the success of Osimertinib - achieving CNS exposure in oncology drug discovery Nicola Colclough, AstraZeneca, UK
- 10:20
- Refreshments, exhibition and posters
- 10:50
- Chemical strategies for activating PINK1, a protein kinase mutated in Parkinson’s disease Youcef Mehellou, Cardiff School of Pharmacy and Pharmaceutical Sciences, UK
- 11:30
- BBB penetrating tetracyclic TRK-selective inhibitor CH7057288: additional efficacy against brain metastasis in vivo model Toshiya Ito, Chugai, Japan
- 12:10
- Interactive session
- 12:45
- Lunch, exhibition and posters
- 13:45
- Discovery of the clinical candidate AZD1390: a high quality, potent and selective inhibitor of ATM kinase with the ability to cross the blood brain barrier Thomas Hunt, AstraZeneca, UK
- 14:25
- Structural mechanisms of regulation of the PI3Ks and related kinases Roger Williams, MRC Laboratory of Molecular Biology, UK
- 15:05
- Closing remarks
- 15:10
- Close of event
Day 1 - 14th May 2018
Event Schedule
- 09:30
- Registration and refreshments
- 10:00
- Opening remarks
- 10:05
- Keynote presentation: Targeting PI3Ks in immunity, infection and cancer Klaus Okkenhaug, University of Cambridge and Babraham Institute, UK
- 10:45
- Discovery and development of a novel, immunosuppressive class of lipid kinase inhibitors able to prolong allogeneic organ engraftment James Reuberson, UCB, UK
- 11:15
- Refreshments, exhibition and posters
- 11:45
- Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Ka that promotes selective degradation of mutant-p110a Emily Hanan, Genentech, USA
- 12:20
- Roger Griffin Memorial Lecture: Inhibitors of the mitotic kinase MPS1: discovery of an orally bioavailable preclinical development candidate Julian Blagg, Institute of Cancer Research, UK
- 13:00
- Lunch, exhibition and posters
- 14:00
- A potent and orally bioavailable ERK1/2 series identified through fragment screening which modulates the phosphorylation and catalytic activity of ERK1/2 Valerio Berdini, Astex Pharmaceuticals, UK
- 14:30
- NVP-LXS196, a novel PKC inhibitor for the treatment of uveal melanoma Julien Papillon, Novartis Institutes for Biomedical Research, USA
- 15:00
- Reserved for late breaker
- 15:30
- Refreshments, exhibition and posters
- 16:00
- flash poster presentations (session 1)
- 16:20
- Identification of low clearance indole acid AMPK activators for the treatment of diabetic nephropathy David Ebner, Pfizer, USA
- 16:35
- New leads from old drugs: repurposing kinase inhibitor chemotypes for tropical diseases Michael Pollastri, Northeastern University, USA
- 17:30
- Flash poster presentations (session 2)
- 17:50
- Network reception, exhibition and posters
- 19:00
- Conference dinner
Accessibility Grants
SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.
Venue and Contact
Fees
Early bird fees before Wednesday 7 February 2018
GB£269 . . . . . . . . . . . . . . . . . SCI / RSC Member
GB£140 . . . . . . . . . . . . . . . . . SCI / RSC Student Member
GB£325 . . . . . . . . . . . . . . . . . Non-Member
GB£159 . . . . . . . . . . . . . . . . . Student Non-Member
Standard fees after Wednesday 7 February 2018
GB£324 . . . . . . . . . . . . . . . . . SCI / RSC Member
GB£168 . . . . . . . . . . . . . . . . . SCI / RSC Student Member
GB£392 . . . . . . . . . . . . . . . . . Non-Member
GB£196 . . . . . . . . . . . . . . . . . Student Non-Member
Late rates for payments received from 12th April onwards. £40 Late payment fee to be added to the above standard rates.
Did you know that as an SCI member you can save on this and future event delegate fees?
Join SCI now; individual membership is only £90 pa (£75 pa direct debit). To find out more click here.
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
For booking terms and conditions click here.
Additional Info
Accommodation
Accommodation options can be found here.
Coach Transport
A coach has been booked to provide transport. This is provided gratis, and you are advised to book your requirements at the time of registration, as the limited number of spaces will be allocated on a "first come, first served" basis. For more information click here.
Exhibition and sponsorship
An exhibition will take place alongside the conference during refreshment breaks for companies and related organisations who may wish to exhibit. For further information and prices, please contact us by email. Spaces are limited and will be allocated on a first come, first served basis.
Students and Bursaries
Discounted rates are offered to SCI and RSC student members, and some student bursaries are available. Please download a bursary application form here. The deadline for bursary applications is 2 April 2018.